Adjuvant radiation therapy improves patient survival in early‐stage merkel cell carcinoma: A 15‐year single‐institution study

Objectives/Hypothesis Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine neoplasm of the skin. Growing evidence supports the benefit of postoperative adjuvant radiation therapy (RT) for locoregional control, but whether it improves overall survival (OS) has been debated. Our objective was to compare the OS of MCC patients who received postoperative RT with those who received surgery alone. Study Design Retrospective case series. Methods Cases of MCC between 2001 and 2016 at the University of California, Los Angeles Health System were reviewed. We identified 87 unique cases of MCC. Among the patients, 74% were identified as male and 26% as female. The average age at diagnosis was 71.2 years. The median survival was 48.0 months. The OS of all the patients at 2 years, 5 years, and 10 years was 54%, 46%, and 26%, respectively. Univariate analysis showed that stage, T stage, N stage, and M stage were significant determinants of OS. The inclusion of RT was not found to be a determinant; however, when restricting the analysis to early‐stage MCC (stages I and II), postoperative adjuvant RT was associated with significantly improved OS. A Cox regression model confirmed that inclusion of RT was an independent prognosticator of OS even when controlled for overall stage and negative margin status. The small sample size and retrospective nature of this study limit its statistical power. Conclusions MCC is an aggressive tumor with a poor prognosis for survival especially in elderly patients. In this study, we found that RT during early‐stage MCC improves OS. Prospective randomized control trials are necessary to validate the observed benefit for MCC patients. Level of Evidence 4 Laryngoscope, 1862–1866, 2018